- Home
- ADCT vs JGH Comparison
ADCT vs JGH Comparison
Compare ADCT & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- JGH
- Stock Information
- Founded
- ADCT 2011
- JGH 2014
- Country
- ADCT Switzerland
- JGH United States
- Employees
- ADCT N/A
- JGH N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- JGH Investment Managers
- Sector
- ADCT Health Care
- JGH Finance
- Exchange
- ADCT Nasdaq
- JGH Nasdaq
- Market Cap
- ADCT 380.2M
- JGH 306.4M
- IPO Year
- ADCT 2020
- JGH N/A
- Fundamental
- Price
- ADCT $3.95
- JGH $12.73
- Analyst Decision
- ADCT Strong Buy
- JGH
- Analyst Count
- ADCT 6
- JGH 0
- Target Price
- ADCT $7.60
- JGH N/A
- AVG Volume (30 Days)
- ADCT 860.1K
- JGH 73.9K
- Earning Date
- ADCT 11-10-2025
- JGH 01-01-0001
- Dividend Yield
- ADCT N/A
- JGH 9.85%
- EPS Growth
- ADCT N/A
- JGH N/A
- EPS
- ADCT N/A
- JGH N/A
- Revenue
- ADCT $77,246,000.00
- JGH N/A
- Revenue This Year
- ADCT $11.78
- JGH N/A
- Revenue Next Year
- ADCT $4.83
- JGH N/A
- P/E Ratio
- ADCT N/A
- JGH N/A
- Revenue Growth
- ADCT 15.73
- JGH N/A
- 52 Week Low
- ADCT $1.05
- JGH $10.36
- 52 Week High
- ADCT $4.80
- JGH $12.85
- Technical
- Relative Strength Index (RSI)
- ADCT 44.05
- JGH 31.13
- Support Level
- ADCT $3.92
- JGH $13.01
- Resistance Level
- ADCT $4.80
- JGH $13.15
- Average True Range (ATR)
- ADCT 0.23
- JGH 0.12
- MACD
- ADCT -0.06
- JGH -0.02
- Stochastic Oscillator
- ADCT 4.32
- JGH 2.00
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.